The Action will concentrate on the activation of the innate and adaptive immune cells (e.g. dendritic cells, innate lymphoid cells type 2 (ILC2), T cells, iNKT cells, antibody class switch), sensitizing route and other biological mechanisms involved in protein up-take and bioavailability. The main questions to be answered are:
1. Which in vitro techniques (or combinations thereof) can be used to predict the sensitizing capacity of a protein?
2. Is it possible to harmonize the protocols for these in vitro techniques among different laboratories and how to validate the models with a set of known allergens and virtually non-allergens?
Other intriguing questions are:
1. Via which route do proteins sensitize and how to test this using in vitro models?
2. Should purified allergens be tested or when processed or when present in matrix and/or processed in a special diet?
3. Is the presence of LPS desirable or, on the contrary, is it a huge problem?
4. Which factors drive antibody class switching, the hallmark of an allergic sensitisation?
This Working Group will collect current knowledge on in vitro methods used for measuring biological effects of proteins (allergens). The identified models will be discussed for their relevance in determining the sensitizing (incl. sensitizing route) properties of proteins. A brainstorm session will be organized to generate new ideas for more predictive in vitro models. The group will elaborate on the most promising models and discuss ways of how to harmonize and validate these models in different laboratories. Next to this a consensus have to be achieved on how to test allergens in these models.
Representatives is this group are gut/lung/skin physiologists, immunologists, biochemists, toxicologists and analytical scientists.
WG 2 DEPUTY LEADER
DR. EDYTA SIENKIEWICZ-SZLAPKA
University of Warmia and Mazury
ul. Oczapowskiego 1a